Evaluate the Effects of Dapagliflozin in Patients With Type 2 Diabetes
Status:
Unknown status
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
This study will make it possible to better understand the mechanisms responsible for the
increase in bad cholesterol levels observed in patients with type 2 diabetes treated with
Dapagliflozin, an antidiabetic treatment made by Astrazeneca.
The information will:
- reveal what is not working properly
- make it possible to choose the most appropriate treatments against cholesterol to
compensate for this impaired functioning
This biomedical research will take place at the University Hospitals of DIJON and NANTES.
- 28 patients will take part: 20 patients will be given Dapagliflozin and 8 patients will
be given the placebo.
- The study treatment will be randomised: patients will be given either Dapagliflozin or
the placebo. The treatment duration is 6 months.
- Moreover, during the inclusion visit and at the end of the study (6 months after the
start of treatment), a kinetics study, to follow the production and elimination of
cholesterol, will be conducted. This will involve administering amino acids that have
been specifically synthesised for this purpose.
- Participation in the study will last 6 months and include 4 protocol visits.